Interim results from a phase I study of lumiliximab (IDEC-152, anti-CD23 antibody) therapy for relapsed or refractory CLL

• BYRD J

収録刊行物

• Blood

  Blood 102 74a-, 2003

詳細情報

• CRID: 1573387450394001664
• NII論文ID: 10021256859
• データソース種別:
  • CiNii Articles